CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation
Aftab Ullah,1 Kaikai Wang,1 Pengkai Wu,1 David Oupicky,1,2 Minjie Sun11State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, People’s Republic of China; 2Center for Drug Delivery and Nanomedicine, Department of Pharmaceutic...
Guardado en:
Autores principales: | Ullah A, Wang K, Wu P, Oupicky D, Sun M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/653270ca995544e8b92a78c7ff1145d1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
DEVELOPMENT AND VALIDATION OF SIMPLE, RAPID AND SENSITIVE UV, HPLC AND HPTLC METHODS FOR THE ESTIMATION OF PIRFENIDONE IN TABLET DOSAGE FORM
por: THORAT,S. G, et al.
Publicado: (2016) -
CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer
por: Xue J, et al.
Publicado: (2020) -
Efecto del ácido alfa lipoico y la pirfenidona en la modulación antioxidante celular contra el daño oxidativo
por: Macias-Barragan,José, et al.
Publicado: (2014) -
Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis
por: Ullah A, et al.
Publicado: (2021) -
Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis [Corrigendum]
por: Ullah A, et al.
Publicado: (2021)